Physician profile
Jeffrey Jackson
NPI 1548412992
$2,698.03
in general payments reported to CMS, 2019-2025
37 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $379 · 2021: $409 · 2022: $440 · 2023: $481 · 2024: $428 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $481.28 | 2019-2025 | Puraply Wound Matrix, Novachor, Puraply |
| Horizon Therapeutics Plc | $311.18 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $273.04 | 2022-2025 | Nuzyra |
| Smith+Nephew, INC. | $199.14 | 2019-2024 | Stravix, Grafix Pl |
| Stryker Corporation | $161.18 | 2020-2025 | Augment Injectable, Prostep, Variax |
| Orthofix Medical, INC. | $142.77 | 2020-2025 | Physio-Stim |
| Medtronic, INC. | $102.83 | 2022-2024 | Intellis Adaptivestim |
| Convatec INC. | $87.71 | 2023-2024 | |
| Access Pro Medical, LLC | $83.98 | 2023 | Matriderm |
| Bioventus LLC | $71.75 | 2021-2022 | |
| Kerecis Limited | $63.17 | 2020-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Averitas Pharma INC. | $55.49 | 2023-2024 | Qutenza |
| Melinta Therapeutics, LLC | $51.17 | 2019 | |
| Mimedx Group, INC. | $51.10 | 2024-2025 | |
| Progenacare Global, LLC | $49.66 | 2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimvie INC. | $47.50 | 2022-2023 | |
| Biowound Solutions, INC. | $38.16 | 2025 | Bio-Connekt |
| Integra Lifesciences Corporation | $37.33 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Revance Therapeutics, INC. | $35.52 | 2024 | Daxxify |
| Dynasplint Systems INC. | $35.37 | 2019 | |
| Advanced Oxygen Therapy INC. | $35.15 | 2023 | Topical Oxygen Chamber For Extremities |
| Next Science LLC | $31.69 | 2023 | Xperience, Surgx, Blastx |
| Alfasigma USA, INC. | $30.34 | 2021 | |
| Heron Therapeutics, INC. | $28.19 | 2021 | |
| Nabriva Therapeutics, Plc | $20.66 | 2022 | |
| Acera Surgical, INC. | $17.27 | 2025 | Restrata Wound Matrix |
| Wright Medical Technology, INC. | $16.36 | 2019 | |
| Djo, LLC | $16.16 | 2019 | |
| Reprise Biomedical, INC. | $15.93 | 2025 | Miro3d |
| Innovation Technologies INC | $15.83 | 2025 | Irrisept |
| Boston Scientific Corporation | $15.35 | 2025 | Accolade Sr |
| Tactile Systems Technology INC | $14.30 | 2020 | |
| Celularity INC. | $14.00 | 2019 | |
| Kci USA, INC. | $13.44 | 2021 | |
| Embody, INC. | $11.64 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.30 | 2019 | |
| Abbvie INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.